Mitsu Onoma

Oral administration of MA-2029, a novel selective and competitive motilin receptor antagonist, inhibits motilin-induced intestinal contractions and visceral pain in rabbits.

T. Peeters, O. Cynshi, K. Yogo, 2008, European journal of pharmacology.

Effects of mitemcinal (GM-611), an orally active erythromycin-derived prokinetic agent, on delayed gastric emptying and postprandial glucose in a new minipig model of diabetes.

S. Ōmura, M. Monnai, K. Yogo, 2008, Journal of diabetes and its complications.

MITEMCINAL (GM‐611), AN ORALLY ACTIVE MOTILIN RECEPTOR AGONIST, IMPROVES DELAYED GASTRIC EMPTYING IN A CANINE MODEL OF DIABETIC GASTROPARESIS

S. Ōmura, S. Hayashi, Y. Kawabe, 2008, Clinical and experimental pharmacology & physiology.

Effects of Oral Mitemcinal (GM-611), Erythromycin, EM-574 and Cisapride on Gastric Emptying in Conscious Rhesus Monkeys

S. Ōmura, K. Yogo, Z. Itoh, 2008, Digestive Diseases and Sciences.

An orally active motilin receptor antagonist, MA-2029, inhibits motilin-induced gastrointestinal motility, increase in fundic tone, and diarrhea in conscious dogs without affecting gastric emptying.

T. Peeters, O. Cynshi, K. Yogo, 2009, European journal of pharmacology.

Effects of Mitemcinal (GM-611), an Acid-Resistant Nonpeptide Motilin Receptor Agonist, on the Gastrointestinal Contractile Activity in Conscious Dogs

S. Ōmura, H. Koga, M. Akima, 2007, Pharmacology.

ORAL MITEMCINAL (GM‐611), AN ERYTHROMYCIN‐DERIVED PROKINETIC, ACCELERATES NORMAL AND EXPERIMENTALLY DELAYED GASTRIC EMPTYING IN CONSCIOUS DOGS

S. Ōmura, H. Koga, M. Akima, 2008, Clinical and experimental pharmacology & physiology.

MITEMCINAL (GM‐611), AN ORALLY ACTIVE MOTILIN RECEPTOR AGONIST, IMPROVES DELAYED GASTRIC EMPTYING IN A CANINE MODEL OF DIABETIC GASTROPARESIS

S. Ōmura, S. Hayashi, Y. Kawabe, 2008, Clinical and experimental pharmacology & physiology.